Bristol Myers Squibb stock rises 5% or more within 6 months of FDA stabilization announcement

Bristol Myers Squibb CEO Chris Boerner highlighted the need for regulatory predictability, which could boost investor confidence. If the FDA commissioner nomination reduces uncertainty, the stock is likely to reflect this stability with a measurable gain.

Implied probability (Yes)

65%